NVIC

COVID-19 Vaccines and Heart Inflammation

Published November 11, 2021

Young males, especially those under the age of 40 years, are at a significant risk of myocarditis and pericarditis following COVID-19 mRNA vaccination.  In particular, males between 12 and 17 years of age are considered at highest risk, with most cases occurring within seven days of receipt of the second vaccine dose. Young women and older adults may also be at risk of heart inflammation; however, the rate is less than that of young males. 

In data presented during the June 23, 2021 Advisory Committee on Immunization Practices (ACIP) meeting, the CDC reported that in females between the age of 12 and 17 years, after the second dose, the case rate of myocarditis/ pericarditis was 9.1 per million doses administered. In males 12 to 17 years of age, however, the rate after the second vaccine dose was 66.7 per one million doses. Cases among females 18 to 24 years old after the second dose were reported at 5.5 per one million doses, while after dose two, males of the same age range were affected at a rate of 56.3 per one million doses. Most cases of myocarditis/pericarditis resulted in hospitalization, and while most were reported as being resolved, the long-term health outcomes were reported to be unknown.  

Multiple published studies have found an increased risk of heart inflammation following mRNA vaccination, especially in young adult males.        

A population-based cohort study published in the British Medical Journal in December 2021 found that the Moderna mRNA COVID-19 vaccine was four times more likely to cause heart inflammation than the Pfizer vaccine.  Additionally, a study published in Nature Medicine in December 2021 reported that men under the age of 40 were more likely to develop myocarditis following Moderna vaccination than following SARS-CoV-2 infection. 

In November 2021, Dr. Steven Gundry, a cardiologist and pioneer of infant heart transplant surgery, issued a warning regarding a significant increase in a common indicator of heart risk in individuals who received mRNA vaccines. The analysis, published in Circulation, notes that: 

“We conclude that the mRNA vacs dramatically increase inflammation on the endothelium and T cell infiltration of cardiac muscle and may account for the observations of increased thrombosis, cardiomyopathy, and other vascular events following vaccination.”

According to Gundry, these significant changes places them at an increased risk for a new Acute Coronary Syndrome, which also includes heart attacks.

Novavax COVID-19 vaccines have also been associated with myocarditis and pericarditis. In vaccine clinical trials, seven cases of heart inflammation were reported, with five occurring within two weeks of vaccination. Four cases were reported in young males. The FDA reports that rates of myocarditis and pericarditis may be higher when the vaccine is administered in the post-authorization period. 

Select disease / vaccine